Published in J Pathol on January 01, 2008
Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol (2010) 1.33
T cell migration, search strategies and mechanisms. Nat Rev Immunol (2016) 1.16
IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood (2012) 1.14
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med (2012) 1.10
Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One (2012) 1.09
Embryonic trafficking of gammadelta T cells to skin is dependent on E/P selectin ligands and CCR4. Proc Natl Acad Sci U S A (2010) 1.08
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest (2014) 1.07
Chemokines and the microenvironment in neuroectodermal tumor-host interaction. Semin Cancer Biol (2008) 0.99
Seasonal variation in vitamin D₃ levels is paralleled by changes in the peripheral blood human T cell compartment. PLoS One (2012) 0.97
Accumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cells. PLoS One (2012) 0.96
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts. PLoS One (2012) 0.94
Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology (2012) 0.93
Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. Blood (2009) 0.93
The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid. PLoS One (2012) 0.88
Expression of the chemokine binding protein M3 promotes marked changes in the accumulation of specific leukocytes subsets within the intestine. Gastroenterology (2009) 0.87
Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model. Dig Dis Sci (2009) 0.86
Memory T-cell trafficking: new directions for busy commuters. Immunology (2010) 0.84
Re-entry of mature T cells to the thymus: an epiphenomenon? Immunol Cell Biol (2008) 0.83
Primed T cell responses to chemokines are regulated by the immunoglobulin-like molecule CD31. PLoS One (2012) 0.83
Molecular mechanisms of induction of antigen-specific allograft tolerance by intranasal peptide administration. J Immunol (2011) 0.83
Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol (2014) 0.83
The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases. Immunology (2015) 0.82
Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther (2013) 0.79
Tissue specific heterogeneity in effector immune cell response. Front Immunol (2013) 0.79
T cell trafficking and metabolism: novel mechanisms and targets for immunomodulation. Curr Opin Pharmacol (2012) 0.78
In the eye of the storm: T cell behavior in the inflammatory microenvironment. Am J Clin Exp Immunol (2013) 0.76
Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice. Clin Mol Allergy (2016) 0.76
OX40 induces CCL20 expression in the context of antigen stimulation: an expanding role of co-stimulatory molecules in chemotaxis. Cytokine (2010) 0.76
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest (2017) 0.75
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. Leuk Lymphoma (2008) 2.14
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia (2006) 2.04
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia (2004) 1.84
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Radio imaging of the very-high-energy gamma-ray emission region in the central engine of a radio galaxy. Science (2009) 1.66
Very-high-energy gamma rays from a distant quasar: how transparent is the universe? Science (2008) 1.65
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
Variable very-high-energy gamma-ray emission from the microquasar LS I +61 303. Science (2006) 1.40
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia (2005) 1.19
Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia (2007) 1.17
Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif (2008) 1.16
Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol (2001) 1.15
Minor H antigens: genes and peptides. Transpl Immunol (2002) 1.09
Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer (1987) 1.09
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol (2001) 1.08
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (2009) 1.07
Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia (2007) 1.01
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol (2001) 0.87
Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant (2001) 0.87
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol (2011) 0.87
Minor H antigens: genes and peptides. Eur J Immunogenet (2001) 0.85
Costimulatory blockade by the induction of an endogenous xenospecific antibody response. Nat Immunol (2000) 0.85
Mesenchymal stem cells for graft-versus-host disease: a double edged sword? Leukemia (2008) 0.85
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol (2009) 0.84
Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia (2010) 0.84
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. Leuk Res (2008) 0.83
Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. Leuk Res (2008) 0.83
The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol (1997) 0.82
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res (2008) 0.82
Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. Haemophilia (2009) 0.81
Cell biology of CML cells. Leukemia (1999) 0.81
Basic research and clinical applications of non-hematopoietic stem cells, 4-5 April 2008, Tubingen, Germany. Cytotherapy (2009) 0.80
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant (1998) 0.80
Progress in characterization, preparation and clinical applications of non-hematopoietic stem cells, 29-30 September 2006, Tübingen, Germany. Cytotherapy (2007) 0.80
Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. Br J Cancer (1988) 0.79
Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Br J Haematol (1997) 0.79
Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol (2007) 0.78
The failure of female cells to present in vitro the male H-Y antigen for secondary cytotoxic T-cell responses. Immunogenetics (1985) 0.78
Role of accessory cells in the induction of a secondary cytotoxic response to Moloney murine sarcoma virus-induced tumors. J Immunol (1983) 0.77
Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer (1987) 0.77
Serum neopterin levels in haematological malignancies. Haematologica (1994) 0.77
Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant (2009) 0.77
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplant (2013) 0.77
Detection of B-cell monoclonality in fine needle aspiration by PCR analysis. Leuk Lymphoma (1998) 0.77
Minor histocompatibility antigens and stem cell transplantation. Vox Sang (2004) 0.76
Biased TCR gene usage in alloreactive T cells specific for a structurally dissimilar MHC alloantigen. Int Immunol (1994) 0.76
Intractable pruritus in non-Hodgkin lymphoma/CLL: rapid response to IFN alpha. Br J Haematol (1996) 0.75
Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant (2009) 0.75
Persistence and specificity of accessory cell impairment in M-MuLV neonatally injected mice. Transplant Proc (1983) 0.75
Marked but transitory elevation of hepatic transaminases after subcutaneous calcium heparin administration. Acta Haematol (1994) 0.75
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib. Drugs Aging (2013) 0.75
[Study of some parameters of blood coagulation and blood gas analysis in a group of aged patients with chronic bronchopneumopathies]. G Clin Med (1979) 0.75
A role for platelet-derived growth factor in drug-induced chronic ergotism? A case report. Angiology (1995) 0.75
Immunosuppression of direct T-cell-mediated xenorecognition in vitro. Transplant Proc (2001) 0.75
Myelodysplastic syndrome and thrombocytosis: a random association? Haematologica (1995) 0.75
[The use of lectins in the histogenesis of adult polycystic kidney]. Minerva Urol Nefrol (1988) 0.75
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. Cancer Chemother Pharmacol (2011) 0.75
[A case of hereditary angioedema undergoing general anesthesia]. Minerva Anestesiol (1991) 0.75
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplant (2005) 0.75
Alpha-interferon treatment of hairy cell leukemia and associated monoclonal large granular lymphocyte proliferation. Haematologica (1992) 0.75
Insulin independence after islet-liver transplantation for metastatic neuroendocrine pancreatic tumor. Transplant Proc (1994) 0.75
High-performance liquid chromatography for the quantitative determination of the urinary metabolites of toluene, xylene, and styrene. Int Arch Occup Environ Health (1982) 0.75
Unexpected low prevalence of FVIII gene inversion in severe hemophilia A patients from north-eastern Italy. Blood Coagul Fibrinolysis (1996) 0.75
Effects of glucagon and octreotide on pig islet insulin release in response to glucose: an in vitro study. Transplant Proc (1994) 0.75
Prolonged duodenal paralysis after PEG placement in a patient with traumatic brain injury: a case report. Eur J Phys Rehabil Med (2010) 0.75
Rearrangement for the T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. Br J Haematol (1987) 0.75
Variability of alpha 1,3-galactosyltransferase splicing isoforms in pig tissues. Transplant Proc (1996) 0.75
[Preliminary study of some parameters of oxygen transport (2,3 DPG) and of acid-base equilibrium of erythrocytes and whole blood in a group of aged subjects]. G Clin Med (1980) 0.75
Medical treatment of hepatocellular carcinoma. Minerva Med (2013) 0.75
Observation of pulsed gamma-rays above 25 GeV from the Crab pulsar with MAGIC. Science (2008) 0.75
Lithium carbonate failed to modify the neutropenia associated with large granular lymphocyte proliferation. Acta Haematol (1989) 0.75
CD25-negative hairy cell leukaemia: intracytoplasmic detection of Tac antigen and interferon-induced surface expression. J Pathol (1995) 0.75
Immunotherapy for chronic myeloid leukaemia. Hematol Cell Ther (1998) 0.75
5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3. Leukemia (2011) 0.75
[Glycosylated hemoglobin in chronic renal insufficiency]. Minerva Med (1981) 0.75
Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant (2012) 0.75
4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost (1998) 0.75
Myasthenic syndrome and oligoclonal lymphocytosis: evolution into chronic lymphocytic leukemia. Ann Hematol (1998) 0.75